These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23595948)

  • 1. A nexus between lipids and multiple sclerosis?
    Zorzon M
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1181. PubMed ID: 23595948
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
    Weinstock-Guttman B; Zivadinov R; Horakova D; Havrdova E; Qu J; Shyh G; Lakota E; O'Connor K; Badgett D; Tamaño-Blanco M; Tyblova M; Hussein S; Bergsland N; Willis L; Krasensky J; Vaneckova M; Seidl Z; Ramanathan M
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1186-91. PubMed ID: 23595944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients.
    Morra VB; Coppola G; Orefice G; De Michele G; Vacca G; Filla A; Bonavita V
    Neurology; 2004 Mar; 62(5):829-30. PubMed ID: 15007146
    [No Abstract]   [Full Text] [Related]  

  • 4. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 5. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Goodin DS
    Neurology; 2006 Sep; 67(6):1104; author reply 1104-5. PubMed ID: 17000997
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.
    Uher T; Fellows K; Horakova D; Zivadinov R; Vaneckova M; Sobisek L; Tyblova M; Seidl Z; Krasensky J; Bergsland N; Weinstock-Guttman B; Havrdova E; Ramanathan M
    J Lipid Res; 2017 Feb; 58(2):403-411. PubMed ID: 27923871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R
    Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
    [No Abstract]   [Full Text] [Related]  

  • 8. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.
    Tola MR; Caniatti LM; Gragnaniello D; Russo M; Stabellini N; Granieri E
    J Neurol; 2003 Jun; 250(6):768-9. PubMed ID: 12862038
    [No Abstract]   [Full Text] [Related]  

  • 9. Rapid onset of ulcerative colitis after treatment with interferon β1a in a patient with multiple sclerosis.
    Tuna Y; Başar O; Dikici H; Köklü S
    J Crohns Colitis; 2011 Feb; 5(1):75-6. PubMed ID: 21272812
    [No Abstract]   [Full Text] [Related]  

  • 10. Rebif offers another option for treating multiple sclerosis.
    Ryan M
    J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
    [No Abstract]   [Full Text] [Related]  

  • 11. Meningioma growth during interferon beta-1A treatment for multiple sclerosis.
    Gama HP; Rocha AJ; Silva CJ; Mendes MF; Veiga JC; Lancellotti CL; Andrade VP; Tilbery CP
    Arq Neuropsiquiatr; 2008 Jun; 66(2B):402-4. PubMed ID: 18641881
    [No Abstract]   [Full Text] [Related]  

  • 12. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson.
    Alsalameh S; Manger B; Kern P; Kalden J
    Arthritis Rheum; 1998 Apr; 41(4):754. PubMed ID: 9550494
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.
    Christopher V; Scolding N; Przemioslo RT
    J Neurol; 2005 Jul; 252(7):855-6. PubMed ID: 15742101
    [No Abstract]   [Full Text] [Related]  

  • 14. Shortcomings in pharmacy benefit forecasting--interferon beta products.
    Rich SJ; Meyer C
    J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
    [No Abstract]   [Full Text] [Related]  

  • 15. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 17. Disease modifying therapies in multiple sclerosis.
    Fox RJ; Fisher E; Rudick R
    Neurology; 2002 Aug; 59(3):471-2; author reply 472-3. PubMed ID: 12177396
    [No Abstract]   [Full Text] [Related]  

  • 18. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of multiple sclerosis with interferon beta-1 b.
    Abdul-Ahad A; Shah S; Galazka A
    Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.